Related references
Note: Only part of the references are listed.ESPAC-3(v2): A multicenter, international, open-label, randomized, controlled phase III trial of adjuvant 5-fluorouracil/folinic acid (5-FU/FA) versus gemcitabine (GEM) in patients with resected pancreatic ductal adenocarcinoma
J. Neoptolemos et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Global Levels of Histone Modifications Predict Prognosis in Different Cancers
David B. Seligson et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Global Histone Modifications in Breast Cancer Correlate with Tumor Phenotypes, Prognostic Factors, and Patient Outcome
Somaia E. Elsheikh et al.
CANCER RESEARCH (2009)
Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
Raphael Marechal et al.
CLINICAL CANCER RESEARCH (2009)
Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
James J. Farrell et al.
GASTROENTEROLOGY (2009)
Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells
William Fazzone et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Epigenetic regulation and molecular characterization of C/EBPα in pancreatic cancer cells
Takashi Kumagai et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Genome-Wide Profiling of Histone H3 Lysine 4 and Lysine 27 Trimethylation Reveals an Epigenetic Signature in Prostate Carcinogenesis
Xi-Song Ke et al.
PLOS ONE (2009)
The global histone modification pattern correlates with cancer recurrence and overall survival in gastric adenocarcinoma
Young Soo Park et al.
ANNALS OF SURGICAL ONCOLOGY (2008)
Pancreatic cancer
Anirban Maitra et al.
ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2008)
Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma - A randomized controlled trial
William F. Regine et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2008)
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation
Satoshi Fujii et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers
Yongkun Wei et al.
MOLECULAR CARCINOGENESIS (2008)
Downregulation of Histone H3 Lysine 9 Methyltransferase G9a Induces Centrosome Disruption and Chromosome Instability in Cancer Cells
Yutaka Kondo et al.
PLOS ONE (2008)
Adjuvant treatments for resectable pancreatic cancer
Hideki Ueno et al.
JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY (2008)
Global histone modifications predict prognosis of resected non-small-cell lung cancer
Fabrice Barlesi et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo
Anthony Tumber et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Histone modifications as markers of cancer prognosis: a cellular view
S. K. Kurdistani
BRITISH JOURNAL OF CANCER (2007)
The mammalian epigenome
Bradley E. Bernstein et al.
CELL (2007)
Cancer epigenomics: DNA methylomes and histone-modification maps
Manel Esteller
NATURE REVIEWS GENETICS (2007)
The cancer epigenome - components and functional correlates
Angela H. Ting et al.
GENES & DEVELOPMENT (2006)
Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells
Ju-Hee Lee et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Genetics and biology of pancreatic ductal adenocarcinoma
Aram F. Hezel et al.
GENES & DEVELOPMENT (2006)
Pharmacogenetics of anticancer drug sensitivity in pancreatic cancer
Elisa Giovannetti et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil
M. Ciaparrone et al.
ONCOLOGY (2006)
Global histone modification patterns predict risk of prostate cancer recurrence
DB Seligson et al.
NATURE (2005)
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer
MF Fraga et al.
NATURE GENETICS (2005)
The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma
J Spratlin et al.
CLINICAL CANCER RESEARCH (2004)
Human pancreatic carcinoma cells activate maspin expression through loss of epigenetic control
M Fitzgerald et al.
NEOPLASIA (2003)
Chromosomal instability and tumors promoted by DNA hypomethylation
A Eden et al.
SCIENCE (2003)
Inactivation of p57KIP2 by regional promoter hypermethylation and histone deacetylation in human tumors
T Kikuchi et al.
ONCOGENE (2002)
Share Paper
